China SXT Pharmaceuticals, Inc. (SXTC)

Market Cap	1.43M -99.2%
Revenue (ttm)	1.14M -34.6%
Net Income	-6.21M
EPS	n/a
Shares Out	477.73K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,705
Open	3.330
Previous Close	3.460
Day's Range	3.000 - 3.340
52-Week Range	3.000 - 83,758.331
Beta	1.89
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2019

About SXTC

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It pr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 4, 2019
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: SXTC
• Website: https://www.sxtchina.com

Financial Performance

In fiscal year 2026, China SXT Pharmaceuticals's revenue was $1.14 million, a decrease of -34.63% compared to the previous year's $1.74 million. Losses were -$6.21 million, 87.8% more than in 2025.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 29, 2026

Data Sources Report a data error